What is KeyCorp's Estimate for Exagen Q3 Earnings?

Key Points

• KeyCorp analysts predict Exagen will report Q3 2025 earnings of ($0.13) per share, maintaining an "Overweight" rating with a $12.00 target price.
• Recently, other analysts including UBS Group and BTIG Research have also reaffirmed buy ratings on Exagen, reflecting positive sentiment among investment analysts.
• Exagen has shown financial volatility, reporting a negative net margin of 28.85% and a negative return on equity of 130.38% in its latest earnings announcement.

Exagen Inc. (NASDAQ:XGN - Free Report) - Equities research analysts at KeyCorp issued their Q3 2025 EPS estimates for shares of Exagen in a report released on Tuesday, July 29th. KeyCorp analyst P. Knight expects that the company will post earnings per share of ($0.13) for the quarter. KeyCorp currently has a "Overweight" rating and a $12.00 price target on the stock. The consensus estimate for Exagen's current full-year earnings is ($0.88) per share. KeyCorp also issued estimates for Exagen's Q4 2025 earnings at ($0.10) EPS and FY2025 earnings at ($0.60) EPS.

Several other equities research analysts have also recently weighed in on XGN. Canaccord Genuity Group upped their target price on Exagen from $8.00 to $11.00 and gave the stock a "buy" rating in a research note on Wednesday, July 30th. BTIG Research restated a "buy" rating on shares of Exagen in a research note on Wednesday, May 7th. Cantor Fitzgerald restated an "overweight" rating and set a $10.00 target price on shares of Exagen in a research note on Wednesday, July 30th. Craig Hallum assumed coverage on Exagen in a research note on Wednesday, July 23rd. They issued a "buy" rating and a $12.00 price target for the company. Finally, UBS Group reiterated an "overweight" rating on shares of Exagen in a research note on Thursday, May 15th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Exagen presently has a consensus rating of "Buy" and an average price target of $11.25.

Exagen Price Performance

Shares of XGN stock traded down $0.10 during trading on Friday, hitting $8.76. The company had a trading volume of 93,880 shares, compared to its average volume of 230,711. The firm has a market capitalization of $192.61 million, a P/E ratio of -9.80 and a beta of 1.61. Exagen has a one year low of $2.24 and a one year high of $9.10. The company has a debt-to-equity ratio of 1.06, a quick ratio of 4.95 and a current ratio of 4.95. The stock's 50-day moving average price is $7.24 and its 200 day moving average price is $5.49.

Exagen (NASDAQ:XGN - Get Free Report) last released its quarterly earnings results on Tuesday, July 29th. The company reported ($0.18) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.18). The firm had revenue of $17.20 million for the quarter, compared to the consensus estimate of $16.25 million. Exagen had a negative return on equity of 130.38% and a negative net margin of 28.85%.

Institutional Trading of Exagen

Institutional investors and hedge funds have recently bought and sold shares of the stock. Toronto Dominion Bank acquired a new stake in Exagen during the 4th quarter worth about $3,655,000. Driehaus Capital Management LLC acquired a new stake in Exagen during the 4th quarter worth about $1,716,000. Kennedy Capital Management LLC grew its holdings in Exagen by 8.8% during the 4th quarter. Kennedy Capital Management LLC now owns 184,473 shares of the company's stock worth $756,000 after acquiring an additional 14,920 shares during the period. Palumbo Wealth Management LLC grew its stake in shares of Exagen by 14.4% in the 1st quarter. Palumbo Wealth Management LLC now owns 99,205 shares of the company's stock valued at $356,000 after buying an additional 12,501 shares during the period. Finally, Geode Capital Management LLC grew its stake in shares of Exagen by 11.9% in the 4th quarter. Geode Capital Management LLC now owns 98,057 shares of the company's stock valued at $402,000 after buying an additional 10,442 shares during the period. 75.25% of the stock is currently owned by institutional investors and hedge funds.

About Exagen

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).